Amazon has entered the GLP-1 weight loss drug market by offering Novo Nordisk's Wegovy pill through its pharmacy service at competitive prices ($25-$149 per month). This move could significantly impact competitors like Hims & Hers, WW International, and GoodRx, as Amazon leverages its 200 million Prime members and e-commerce platform. While the pill form is expected to drive overall GLP-1 adoption, Amazon's scale and reach pose a competitive threat to specialized GLP-1 retailers.

Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.

Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.

The telepharmacy market is projected to grow from $10.06 billion in 2024 to $21.89 billion by 2032, with a 10.23% annual growth rate. The market is driven by technological advancements, reducing healthcare disparities, and expanding digital pharmacy access, particularly in rural areas.

GoodRx announced a collaboration with Novo Nordisk to offer Ozempic and Wegovy pens at $499/month for eligible self-paying patients, expanding medication access and meeting growing demand for GLP-1 medications.

Sesame, a healthcare marketplace, is offering no-cost virtual healthcare appointments to Los Angeles residents affected by wildfires, including primary care, prescription refills, and mental health medication management.

GoodRx's Q3 2023 earnings missed analyst estimates, with revenue and guidance falling short. The company's stock price dropped nearly 19% as a result, despite growth in key metrics like prescription transactions and monthly active consumers. Increased competition, particularly from Amazon's push into same-day pharmaceutical delivery, is seen as a challenge for GoodRx's future performance.

RBC Capital maintained its Outperform rating on GoodRx Holdings Inc. with a steady price target of $10.00. The upcoming quarterly report is anticipated to focus on the growth of Monthly Active Consumers, a key metric for the firm. RBC expects this growth to support GoodRx's guidance of mid-single-digit percentage revenue growth and an EBITDA margin surpassing 30%.

Throughout the last three months, 7 analysts have evaluated GoodRx Holdings (NASDAQ:GDRX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for GoodRx Holdings, presenting an average target of $10.64, a high estimate of $16.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 12.0% from the previous average price target of $9.50. Analyzing Analyst Ratings: A Detailed Breakdown A clear picture of GoodRx Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Craig Hettenbach Morgan Stanley Raises Equal-Weight $9.50 $7.00 Mark Mahaney RBC Capital Raises Outperform $10.00 $8.00 Stephanie Davis Barclays Raises Overweight $10.00 $9.00 John Ransom Raymond James Announces Outperform $10.00 - Charles Rhyee TD Cowen Raises Buy $16.00 $14.00 Scott Schoenhaus Keybanc Announces Overweight $9.00 - Stan Berenshteyn Wells Fargo Announces Overweight $10.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects ...Full story available on Benzinga.com

RBC Capital Markets issued an upgrade for GoodRx Holdings Inc (NASDAQ:GDRX) shares. The analyst stated the Integrated Savings Program (ISP) and direct contracting (DC) initiatives, along with the expansion of its manufacturing solutions business, offered significant new growth opportunities and strengthened the stability of its core Rx transaction business. Related: Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024. “We think this ‘hybrid’ approach presents both some incremental revenue opportunity while also better insulating GDRX from PBM-retailer disruptions like what happened with Kroger in mid-2022,” RBC wrote. GoodRx announced a new direct contracting agreement with Kroger Co. (NYSE:KR) earlier this ...Full story available on Benzinga.com

In the latest quarter, 13 analysts provided ratings for GoodRx Holdings (NASDAQ:GDRX), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 6 6 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 2 0 0 0 3M Ago 0 4 6 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $9.46, with a high estimate of $16.00 and a low estimate of $7.50. Observing a 16.65% increase, the current average has risen from the previous average price target of $8.11. Analyzing Analyst Ratings: A Detailed Breakdown The standing of GoodRx Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Charles Rhyee TD Cowen Raises Buy $16.00 $14.00 Scott Schoenhaus Keybanc Announces Overweight $9.00 - Stan Berenshteyn Wells Fargo Announces Overweight $10.00 - Sean Dodge RBC Capital Maintains Sector Perform $8.00 - Stan Berenshteyn Wells Fargo Raises Equal-Weight $7.50 $6.00 Eric Sheridan UBS Raises Neutral $8.00 $5.00 Sean Dodge RBC Capital Raises Sector Perform $8.00 $7.00 Eric Sheridan Goldman Sachs Raises Neutral $7.50 $6.50 Jailendra Singh Truist Securities Raises Hold $8.00 $7.50 Charles Rhyee TD Cowen Raises Outperform $14.00 $12.00 Lisa Gill JP Morgan Raises Overweight $10.00 $7.00 Steve Valiquette Barclays Raises Overweight $9.00 $8.00 Michael Cherny Leerink Partners Announces Outperform $8.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ...Full story available on Benzinga.com

Upcoming U.S. retail sales and CPI reports could impact Federal Reserve interest rate cut expectations.